Table of Contents
Nrt Smoking Cessation Aids in Israel
Euromonitor International
May
2009
List of Contents and Tables
Executive Summary
2008 Continues
Positive Growth Rates Similar To the Review Period
Demand for More
Specific Treatments Leads To New Innovations and Launches
Private Label
Benefits From Unique Market Structure
Gsl Revolution Did Not Bring
Expected Results
Economic Slowdown Aside, Some Sectors Are Expected To See
Strong Growth
Key Trends and Developments
Unusual Market Structure
With OTC Drugs Falling in the "health Basket"
Increased Private Label
Activity
Specific Drugs Answer Consumer Demand for Specification
Gsl
Revolution Failed To Impact the Retail Market As Expected
Economic
Slowdown Is Expected Only in 2009
Market Indicators
Table 1 Consumer
Expenditure on Health Goods and Medical Services 2003-2008
Table 2 Life
Expectancy at Birth 2003-2008
Market Data
Table 3 Sales of OTC
Healthcare by Sector: Value 2003-2008
Table 4 Sales of OTC Healthcare by
Sector: % Value Growth 2003-2008
Table 5 OTC Healthcare Company Shares by
Value 2004-2008
Table 6 OTC Healthcare Brand Shares by Value 2005-2008
Table 7 Penetration of Private Label by Sector 2003-2008
Table 8 Sales of
OTC Healthcare by Distribution Format: % Analysis 2003-2008
Table 9 Sales
of OTC Healthcare by Sector and Distribution Format: % Analysis 2008
Table
10 Forecast Sales of OTC Healthcare by Sector: Value 2008-2013
Table 11
Forecast Sales of OTC Healthcare by Sector: % Value Growth 2008-2013
Appendix
OTC Registration and Classification
Vitamins and Dietary
Supplements Registration and Classification
Self-medication and Preventive
Medicine
Generics
Switches
Summary 1 OTC Healthcare Switches
2005-2007
Definitions
Summary 2 Research Sources
Dexxon Ltd
Strategic Direction
Key Facts
Summary 3 Dexxon Ltd: Key Facts
Summary 4 Dexxon Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 5 Dexxon Ltd: Competitive
Position 2008
New-pharm Drugstores Ltd
Strategic Direction
Key
Facts
Summary 6 New-Pharm Drugstores Ltd: Key Facts
Summary 7
New-Pharm Drugstores Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Rekah Pharmaceutical Products
Ltd
Strategic Direction
Key Facts
Summary 8 Rekah Pharmaceutical
Products Ltd: Key Facts
Summary 9 Rekah Pharmaceutical Products Ltd:
Operational Indicators
Company Background
Production
Competitive
Positioning
Summary 10 Rekah Pharmaceutical Products Ltd: Competitive
Position 2008
Super-pharm (israel) Ltd
Strategic Direction
Key
Facts
Summary 11 Super Pharm Israel Ltd: Key Facts
Summary 12 Super
Pharm Israel Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Teva Pharmaceutical Industries
Ltd
Strategic Direction
Key Facts
Summary 13 Teva Pharmaceutical
Industries Ltd: Key Facts
Summary 14 Teva Pharmaceutical Industries Ltd:
Operational Indicators
Company Background
Production
Competitive
Positioning
Summary 15 Teva Pharmaceutical Industries Ltd: Competitive
Position 2008
Trima Israel Pharmaceutical Products Maabarot Ltd
Strategic Direction
Key Facts
Summary 16 Trima Israel Pharmaceutical
Products Maabarot Ltd: Key Facts
Summary 17 Trima Israel Pharmaceutical
Products Maabarot Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 18 Trima Israel
Pharmaceutical Products Maabarot Ltd Competitive Position 2008
Headlines
Trends
Switches
Competitive Landscape
Prospects
Sector Indicators
Table 12 Number of Smokers by Gender 2003-2008
Sector Data
Table 13 Sales of Smoking Cessation Aids by Subsector: Value
2003-2008
Table 14 Sales of Smoking Cessation Aids by Subsector: % Value
Growth 2003-2008
Table 15 NRT Gum Flavours: % Value Breakdown
2006-2008
Table 16 Smoking Cessation Aids Company Shares by Value
2004-2008
Table 17 Smoking Cessation Aids Brand Shares by Value
2005-2008
Table 18 Forecast Sales of Smoking Cessation Aids by Subsector:
Value 2008-2013
Table 19 Forecast Sales of Smoking Cessation Aids by
Subsector: % Value Growth 2008-2013
| 
View Cart
